Leonabio, Inc. (LONA) has disclosed a new risk, in the Innovation / R&D category.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Leonabio, Inc. faces significant uncertainty in successfully integrating lasofoxifene into its existing pipeline, as the program will demand substantial additional capital for preclinical and clinical development as well as regulatory approval. The company may encounter higher-than-expected integration and operating costs, unknown liabilities, operational disruptions, and potential asset impairments, any of which could materially and adversely affect its business, financial condition, and overall prospects.
Overall, Wall Street has a Moderate Buy consensus rating on LONA stock based on 2 Buys.
To learn more about Leonabio, Inc.’s risk factors, click here.